Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Placebo-controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin®)

NCT01009918 is registered in ClinicalTrials.gov with University of South Florida as lead sponsor.

NCT NCT01009918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01009918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Placebo-controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin®)
Lead sponsor
University of South Florida
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2018
Enrollment
468 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cardiac toxicity